Bicara Therapeutics (BCAX) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Geron (GERN) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 22.3% versus a loss of 53.2%. Geron is the larger company by market cap ($560.9 million vs $560.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | GERN |
|---|---|---|
| Share price | $8.44 | $0.8707 |
| Market cap | $560.31M | $560.94M |
| 1-day change | -7.46% | -4.63% |
| YTD return | -49.85% | -34.04% |
| 1-year return | -53.22% | -22.26% |
| 5-year return | — | -40.77% |
| Forward P/E | — | 9.67 |
| EPS (TTM) | $-3.46 | $-0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-137.95M | $-83.50M |
| 52-week high | $30.99 | $2.01 |
| 52-week low | $7.87 | $0.84 |
| Distance from 52-week high | -72.77% | -56.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +281.16% | +301.98% |
| Average volume | 1.20M | 13.05M |
| Shares outstanding | 66.39M | 644.24M |
| Employees | 103 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GERN has outperformed BCAX by 31.0 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
BCAX vs GERN FAQ
Which is bigger, Bicara Therapeutics or Geron?
Geron (GERN) is larger, with a market capitalization of $560.94M compared with $560.31M for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or GERN?
GERN returned -22.26% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.